Recent Analysts’ Ratings Updates for IDEAYA Biosciences (IDYA)

A number of research firms have changed their ratings and price targets for IDEAYA Biosciences (NASDAQ: IDYA):

• 7/16/2024 – IDEAYA Biosciences had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $54.00 price target on the stock, down previously from $56.00.
• 7/12/2024 – IDEAYA Biosciences had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $69.00. They now have an “overweight” rating on the stock.
• 7/11/2024 – IDEAYA Biosciences had its price target raised by analysts at Royal Bank of Canada from $53.00 to $61.00. They now have an “outperform” rating on the stock.
• 7/9/2024 – IDEAYA Biosciences had its price target raised by analysts at BTIG Research from $55.00 to $62.00. They now have a “buy” rating on the stock.
• 7/8/2024 – IDEAYA Biosciences had its price target raised by analysts at Oppenheimer Holdings Inc. from $53.00 to $60.00. They now have an “outperform” rating on the stock.
• 7/8/2024 – IDEAYA Biosciences had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $56.00 price target on the stock, up previously from $52.00.
• 7/8/2024 – IDEAYA Biosciences is now covered by analysts at Mizuho. They set an “outperform” rating and a $50.00 price target on the stock.
• 7/8/2024 – IDEAYA Biosciences had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $63.00 price target on the stock.
• 6/4/2024 – IDEAYA Biosciences had its price target raised by analysts at Stifel Nicolaus from $55.00 to $63.00. They now have a “buy” rating on the stock.

IDEAYA Biosciences Price Performance

NASDAQ IDYA traded down $1.94 during trading hours on Wednesday, hitting $40.71. The company had a trading volume of 836,519 shares, compared to its average volume of 934,444. IDEAYA Biosciences, Inc. has a fifty-two week low of $20.90 and a fifty-two week high of $47.74. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of -20.25 and a beta of 0.86. The firm’s 50 day moving average is $38.25 and its 200 day moving average is $40.91.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. During the same quarter in the previous year, the firm earned ($0.49) earnings per share. The company’s quarterly revenue was down 100.0% compared to the same quarter last year. On average, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -2.37 EPS for the current year.

Insider Activity

In other news, CEO Yujiro S. Hata sold 34,433 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $41.81, for a total transaction of $1,439,643.73. Following the completion of the transaction, the chief executive officer now directly owns 677,887 shares in the company, valued at $28,342,455.47. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 56,711 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total value of $2,359,744.71. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at $28,206,878.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yujiro S. Hata sold 34,433 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $41.81, for a total value of $1,439,643.73. Following the completion of the sale, the chief executive officer now owns 677,887 shares of the company’s stock, valued at $28,342,455.47. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 119,644 shares of company stock valued at $4,832,228. 3.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IDEAYA Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Covestor Ltd raised its stake in IDEAYA Biosciences by 9,225.0% during the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock valued at $49,000 after purchasing an additional 1,107 shares during the period. Comerica Bank raised its stake in IDEAYA Biosciences by 723.5% during the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after purchasing an additional 1,324 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new stake in IDEAYA Biosciences during the 1st quarter valued at $67,000. SG Americas Securities LLC acquired a new position in shares of IDEAYA Biosciences in the first quarter worth $101,000. Finally, AJOVista LLC acquired a new position in shares of IDEAYA Biosciences in the fourth quarter worth $99,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.